Search

Your search keyword '"eculizumab"' showing total 7,713 results

Search Constraints

Start Over You searched for: Descriptor "eculizumab" Remove constraint Descriptor: "eculizumab"
7,713 results on '"eculizumab"'

Search Results

1. United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use.

7. Eculizumab for Shiga-toxin-induced hemolytic uremic syndrome in adults with neurological involvement.

19. Bilateral Retinal Venous Occlusion in Atypical Hemolytic-Uremic Syndrome Due to Complement Factor H Mutation.

20. Spontaneous Extradural Hematoma in a Sickle Cell Anemia Patient with Hyperinflammation and Thrombotic Microangiopathy Successfully Treated with Eculizumab: A Case Report and Review of the Literature.

21. Anti-CFH-associated hemolytic uremic syndrome: do we still need plasma exchange?

22. Using genetics to explore complement C5 as a druggable protein in periodontitis.

23. Carfilzomib-induced thrombotic microangiopathy (TMA) refractory to eculizumab: A case report and literature review.

24. Thrombotische Mikroangiopathie als seltene Komplikation nach Lungentransplantation.

25. Systemic lupus erythematosus presenting with atypical hemolytic uremic syndrome: a case report and review of the literature.

26. Meningococcal Carriage in Children with Atypical Hemolytic Uremic Syndrome Receiving Eculizumab Therapy.

27. Lupusnephritis und assoziierte thrombotische Mikroangiopathie.

28. Case report: Timing of eculizumab treatment in catastrophic antiphospholipid syndrome.

29. Closing remarks from the IIGANN2023 Tokyo symposium—40 years of study progress in IgA nephropathy.

30. Distinctive antibody responses to Mycobacterium tuberculosis in pulmonary and brain infection.

31. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.

32. Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial.

33. Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab.

34. Thrombotic microangiopathy (TMA) associated with pregnancy: role of the clinical laboratory in differential diagnosis.

35. Microangiopatía trombótica (MAT) asociada al embarazo: papel del laboratorio clínico en el diagnóstico diferencial.

36. Monocyte NLRP3 inflammasome and interleukin-1β activation modulated by alpha-1 antitrypsin therapy in deficient individuals.

37. Targeted management of coexistent severe thrombophilias—A case report of a successful pregnancy despite paroxysmal nocturnal hemoglobinuria and hereditary protein C deficiency

38. Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU) (EspacECU)

42. Protein-losing enteropathy as a new phenotype in atypical hemolytic uremic syndrome caused by CD46 gene mutation.

43. Annual trends in atypical haemolytic uremic syndrome management in Japan and factors influencing early diagnosis and treatment: a retrospective study

44. Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS– real-world data

45. Eculizumab for Shiga‐toxin‐induced hemolytic uremic syndrome in adults with neurological involvement

46. Identification of potential C1-binding sites in the immunoglobulin CL domains.

47. Eculizumab use throughout pregnancy in two patients with aquaporin‐4‐positive neuromyelitis optica spectrum disorder.

48. PIK3CA inhibition in models of proliferative glomerulonephritis and lupus nephritis.

49. Kidney Disease and Antinephrin Antibodies.

50. Stable responses to danicopan as add-on to ravulizumab in two patients with paroxysmal nocturnal hemoglobinuria.

Catalog

Books, media, physical & digital resources